TransTech Alzheimer’s disease therapy wins FDA fast track status

TTP488 prevents interaction of a material found in the Alzheimer’s patients cells, referred to as amyloid beta (Aß).

The candidate is the first drug related to Receptor for Advanced Glycation Endproducts, the immunoglobulin supergene family of molecules.

TransTech Pharma chairman and chief executive officer Dr. Adnan Mjalli said, "This development reflects a recognition that TT488 has the potential to address huge unmet medical needs for the treatment of millions of patients suffering from Alzheimer’s disease, a devastating and life-threatening disease with profound consequences for our aging population."